Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature

Value in Health (Impact Factor: 2.89). 08/2009; 12(6):915 - 922. DOI: 10.1111/j.1524-4733.2009.00539.x

ABSTRACT Objectives:  Information on the health care costs associated with nonadherence to treatments for diabetes is both limited and inconsistent. We reviewed and critically appraised the literature to identify the main methodological issues that might explain differences among reports in the relationship of nonadherence and costs in patients with diabetes.Methods:  Two investigators reviewed Medline, EMBASE, Cochrane library and CINAHL and studies with information on costs by level of adherence in patients with diabetes published between January 1, 1997 and September 30th 2007 were included.Results:  A total of 209 studies were identified and ten fulfilled the inclusion criteria. All included studies analyzed claims data and 70% were based on non-Medicaid and non-Medicare databases. Low medication possession ratios were associated with higher costs. Important differences were found in the ICD-9/ICD-9 CM codes used to identify patients and their diagnoses, data sources, analytic window period, definitions of adherence measures, skewness in cost data and associated statistical issues, adjustment of costs for inflation, adjustment for confounders, clinical outcomes and costs.Conclusions:  Important variation among cost estimates was evident, even within studies of the same population. Readers should be cautious when comparing estimated coefficients from various studies because methodological issues might explain differences in the results of costs of nonadherence in diabetes. This is particularly important when estimates are used as inputs to pharmacoeconomic models.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The common approach to modeling healthcare cost data is to use aggregated total cost from multiple categories or sources (e.g. inpatient, outpatient, prescriptions, etc.) as the dependent variable. However, this approach could hide the differential impact of covariates on the different cost categories. An alternative is to model each cost category separately. This could also lead to wrong conclusions due to failure to account for the interdependence among the multiple cost outcomes. Therefore, we propose a multivariate generalized linear mixed model (mGLMM) that allows for joint modeling of longitudinal cost data from multiple sources. We assessed four different approaches, (1) shared random intercept, (2) shared random intercept and slope, (3) separate random intercepts from a joint multivariate distribution, and (4) separate random intercepts and slopes from a joint multivariate distribution. Each of these approaches differs in the way they account for the correlation among the multiple cost outcomes. Comparison was made via goodness of fit measures and residual plots. Longitudinal cost data from a national cohort of 740,195 veterans with diabetes (followed from 2002–2006) was used to demonstrate joint modeling. Among examined models, the separate random intercept approach exhibited the lowest AIC/BIC in both log-normal and gamma GLMMs. However, for our data example, the shared random intercept approach seemed to be sufficient as the more complex models did not lead to qualitatively different conclusions.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Treatment of type 2 diabetes mellitus (T2DM) often requires combinations of antihyperglycemic medications with complementary mechanisms of action. Inadequate adherence to combination therapy, which may be related to pill burden (greater number of pills and higher administration frequency) and poor tolerability, may lead to suboptimal clinical outcomes. One potential means of addressing these problems is the use of fixed-dose combinations (FDCs), which simplify the treatment regimen by reducing pill burden, compared with the same combination delivered as separate pills. The present study evaluates the efficacy and tolerability of FDCs in the treatment of T2DM patients, and provides an overview of dosing, costs, and adherence.Methods: A review of FDCs, with attention to those that contain metformin extended-release (XR) and allow once-daily dosing.Results: Many FDCs contain metformin as one of the component drugs. However, the standard immediate-release (IR) formulation of metformin requires twice-daily dosing and may have tolerability problems related to gastrointestinal adverse effects. The XR formulations of metformin can be administered once daily and have been shown to reduce the occurrence of gastrointestinal effects frequently observed with IR metformin; consequently, they may have significant advantages for inclusion in FDCs. The long-term cost-effectiveness of FDCs has yet to be fully determined.Conclusion: For patients taking metformin, FDCs containing metformin XR offer equivalent efficacy with reduced dose frequency and, potentially, fewer gastrointestinal events compared with standard IR formulation, as well as a reduced number of pills compared with separate-pill regimens. By reducing pill burden and improving tolerability, FDCs may improve adherence.
    Endocrine Practice 11/2014; 1(-1):1-32. DOI:10.4158/EP14259.RA · 2.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to elicit patients' beliefs about taking their oral antidiabetic drugs (OADs) as prescribed to inform the development of sound adherence-enhancing interventions. A qualitative study was performed. Adults with type 2 diabetes who had been taking an OAD for >3 months were solicited to participate in one of six focus groups. Discussions were facilitated using a structured guide designed to gather beliefs related to important constructs of the theory of planned behavior. Four coders using this theory as the theoretical framework analyzed the videotaped discussions. Forty-five adults participated. The most frequently mentioned advantages for OAD-taking as prescribed were to avoid long-term complications and to control glycemia. Family members were perceived as positively influential. Carrying the OAD at all times, having the OAD in sight, and having a routine were important facilitating factors. Being away from home, not accepting the disease, and not having confidence in the physician's prescription were major barriers to OAD-taking. This study elicited several beliefs regarding OAD-taking behavior. Awareness of these beliefs may help clinicians adjust their interventions in view of their patients' beliefs. Moreover, this knowledge is crucial to the planning, development, and evaluation of interventions that aim to improve medication adherence.
    Patient Preference and Adherence 01/2015; 9:413-20. DOI:10.2147/PPA.S78628 · 1.49 Impact Factor